Promising ITP drug trial pulled before it even started
NCT ID NCT06291415
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any participants, so no results are available. It would have included adults who had not responded to at least one prior ITP treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HMPL-523 (sovleplenib), a Syk inhibitor
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Canberra Hospital
Canberra, Australia
-
Center for Cancer and Blood Disorders
Bethesda, Maryland, 20817, United States
-
Charite university
Berlin, 10117, Germany
-
Childrens Hospital of California
Irvine, California, 92868, United States
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
East Carolina University, Brody School of Medicine
Greenville, North Carolina, 27834, United States
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Georgetown University Medical Center - Georgetown Lombardi Comprehensive Cancer Center
Georgetown, Delaware, 20007, United States
-
Hospital Gregorio Maranon Madrid
Madrid, 28007, Spain
-
Hospital Infanta Leonor
Madrid, 28031, Spain
-
Hospital Morales Meseguer
Murcia, 30008, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital del Mar Barcelona
Barcelona, 08003, Spain
-
Marien Hospital Dusseldorf
Düsseldorf, 40479, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, 74146, United States
-
Oslo University Hospital
Oslo, Norway
-
Peninsula Private Hospital
Frankston, Victoria, Australia
-
Royal Adelaide Hospital
Adelaide, Australia
-
San Juan Oncology Associates
Farmington, New Mexico, 87401, United States
-
Sykehuset Ostfold Kalnes (fosta) / Osfold Hospital Trust (MSL)
Grålum, 1714, Norway
-
Taussig Cancer Institute
Cleveland, Ohio, 44106, United States
-
Texas Oncology San Antonio Medical Center
San Antonio, Texas, 78240, United States
-
The Perth Blood Institute (PBI) Hollywood Specialist Centre
West Perth, Western Australia, Australia
-
UMG Gottingen Hämatologie
Göttingen, Germany
-
University Hospital of Schleswig-Holstein, Department of Haematology and Oncology
Lübeck, Germany
-
University de Burgos
Burgos, 09001, Spain
-
University of Washington (UW) Medical Center
Seattle, Washington, 98195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a new dissolvable dressing stop surgical bleeding faster?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Can engineered immune cells tame autoimmune disease?